세계의 항오심제 시장(2024-2031년)

Global Antinauseants Market - 2024-2031

상품코드PH4125
발행기관DataM Intelligence
발행일2024.08.06
페이지 수182 Pages
포맷PDF + EXCEL
커버리지Global

₩6,525,000 – ₩11,775,000

보고서 요약(국문)

개요
전 세계 항구토제 시장은 2023년 23억 달러 규모에 달했으며, 2024년부터 2031년까지 연평균 6.2%의 성장률을 보이며 2031년에는 37억 달러에 이를 것으로 예상됩니다.
항구토제는 메스꺼움과 구토를 예방하거나 완화하는 데 도움을 주는 약물입니다. 이러한 증상은 흔하게 나타나며 다양한 질환, 치료법, 시술 및 약물로 인해 발생할 수 있습니다. 구토는 위장관의 독성 물질을 배출하려는 신체의 보호 반사 작용으로 여겨지지만, 특히 심각한 탈수 증상이 있는 경우 구토를 억제하기 위해 항구토제가 필요한 경우가 많습니다.
이러한 약물은 멀미, 항암화학요법으로 인한 메스꺼움과 구토, 수술 후 메스꺼움과 구토 등의 치료에 자주 사용됩니다. 시장 성장은 암 및 위장염 발병률 증가와 연구 개발 활동의 활성화와 같은 요인에 의해 주도되고 있습니다.

시장 동향: 주요 동인
암 및 위장염 발병률 증가
전 세계 항구토제 시장 수요는 여러 요인에 의해 주도되고 있습니다. 시장을 이끄는 주요 요인 중 하나는 암 발병률 증가와 항암화학요법 치료 증가입니다. 항암화학요법으로 인한 오심 및 구토(CINV)는 항구토제 사용이 필요한 흔한 부작용입니다.
2023년 7월 미국 국립보건원(NIH) 발표에 따르면, 암 환자의 약 70~80%가 항암화학요법으로 인한 오심 및 구토(CINV)를 경험합니다. CINV는 암 치료와 관련된 가장 고통스러운 증상 중 하나이며, 항암화학요법 순응도 저하와 관련이 있습니다.
마찬가지로, 전 세계적으로 위장염 발병률이 높은 것도 항구토제 수요 증가에 기여하고 있습니다. 위장염 치료는 오심 및 구토와 같은 여러 부작용을 유발합니다. 항구토제는 치료 중 이러한 부작용을 조절하는 데 유용합니다.

또한, 주요 기업들의 인식 제고 프로그램과 신약 승인은 이 지역 시장 성장을 촉진할 것입니다. 예를 들어, 2023년 10월 아스텔라스 파마(Astellas Pharma Inc.)는 유럽 종양학회(ESMO) 2023 학술대회에서 연구 결과를 발표했습니다. 이 발표에서 아스텔라스 파마는 페럿을 대상으로 항구토제가 위 손상 및 구토 빈도에 미치는 영향에 대한 초록을 발표했습니다.
또한, 2022년 4월 이보크 파마(Evoke Pharma, Inc.)는 미국 식품의약국(FDA)으로부터 기모티(메토클로프라미드) 비강 스프레이에 대한 신약 독점권을 획득했습니다. 이보크는 해치-왁스만 법(Hatch-Waxman Act)에 따라 최초 승인일로부터 3년간 독점적인 판매 권한을 확보하여 제네릭 의약품과의 경쟁으로부터 제품을 보호할 수 있게 되었습니다. 메토클로프라미드는 강력한 항구토제로 사용되는 도파민 길항제입니다.

제약 요인
약물 관련 부작용, 개인의 인식 부족, 제한된 치료 접근성, 엄격한 규제 요건 등의 요인이 시장 성장을 저해할 것으로 예상됩니다.
이 보고서에 대한 자세한 내용은 샘플을 요청하십시오.
세그먼트 분석
세계 항구토제 시장은 약물 유형, 적용 분야, 유통 채널 및 지역별로 세분화됩니다.
세로토닌 수용체 길항제 부문은 세계 항구토제 시장 점유율의 약 45.3%를 차지했습니다.
세로토닌 수용체 길항제 부문은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 5HT3 길항제는 수술 후 및 항암 화학 요법 중 항구토제로 일상적으로 사용됩니다. 여기에는 아자세트론, 그라니세트론, 인디세트론, 온단세트론, 팔로노세트론, 돌라세트론, 라모세트론, 트로피세트론 등 다수의 출시 제품이 포함됩니다.

또한, 업계 주요 기업의 신약 출시 및 승인, 그리고 인식 개선 프로그램 등이 이 부문의 성장을 견인할 것입니다. 예를 들어, 2024년 7월, 암닐 파마슈티컬스(Amneal Pharmaceuticals, Inc.)는 즉시 사용 가능한 주사제인 포신베즈(FOCINVEZ) 출시를 발표했습니다. 다른 포사프레피탄트 제제와 달리, 이 1회용 바이알 제품은 폴리소르베이트 80을 함유하지 않고, 재구성이나 희석이 필요 없으며, 동봉된 바이알 걸이를 사용하여 바이알에서 직접 투여할 수 있습니다.
포신베즈와 신반티(Cinvanti)는 세로토닌(5-HT3) 수용체 길항제 및 코르티코스테로이드(일반적으로 덱사메타손)와 병용하여 급성 및 지연성 메스꺼움과 구토 치료에 사용하도록 권장됩니다. 주사제 포신베즈는 다른 항구토제와 병용하여 성인 및 6개월 이상 소아 환자에게 투여할 수 있습니다.

2022년 5월 캐나다 보건 연구소(Canadian Institutes of Health Research)에서 발표한 기사에 따르면, 온단세트론(Ondansetron)은 캐나다에서 항구토제로 승인된 5-HT3 길항제입니다. 이 약물은 항암 화학 요법 및 수술 후 발생하는 메스꺼움과 구토에 사용됩니다.
지역 분석
북미는 전 세계 항구토제 시장의 약 42.2%를 차지했습니다.
북미 지역은 미국에서 암 및 항암 화학 요법으로 인한 메스꺼움과 구토(CINV) 및 위장염의 발생률 증가로 인해 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상되며, 이는 해당 지역 시장 성장을 견인할 것입니다.
미국 암 협회(American Cancer Society)에 따르면, 2023년 12월 미국에서는 약 609,820명의 암 사망자와 1,958,310건의 새로운 암 환자가 발생할 것으로 추정됩니다. 따라서 구토와 메스꺼움을 유발하는 이러한 질환의 발생률 증가는 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다.

또한, 기업 인수합병 및 신약 승인과 같은 주요 업계 전략은 이 지역 시장 성장을 촉진할 것입니다. 예를 들어, 2022년 1월, 컴벌랜드 파마슈티컬스(Cumberland Pharmaceuticals Inc.)는 일본 교와 키린(Kyowa Kirin Co., Ltd.)의 미국 자회사인 교와 키린으로부터 FDA 승인을 받은 항암 보조 치료제인 산쿠소(SANCUSO, 그라니세트론 경피 패치)를 인수하는 최종 계약을 체결하고 완료했다고 발표했습니다. 산쿠소는 특정 유형의 항암 화학 요법 치료를 받는 환자의 메스꺼움과 구토를 예방하기 위해 FDA 승인을 받은 최초이자 유일한 처방 패치입니다.
또한, 2022년 9월, 헤론 테라퓨틱스(Heron Therapeutics, Inc.)는 미국 식품의약국(FDA)이 성인의 수술 후 메스꺼움과 구토(PONV) 예방을 위한 정맥 주사용 주사제인 아폰비(APONVIE, 아프레피탄트)를 승인했다고 발표했습니다.

시장 세분화
약물 유형별
• 세로토닌 수용체 길항제
• 항콜린제
• 글루코코르티코이드
• 도파민 수용체 길항제
• 뉴로키닌 수용체 길항제
• 기타
적용 분야별
• 항암 화학 요법
• 위장염
• 수술 후 관리
• 기타
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 한국
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
항메스꺼움제 시장의 주요 글로벌 업체로는 Heron Therapeutics, Inc. 등이 있습니다. TAIHO PHARMACEUTICAL CO., LTD, Pfizer Inc., Merck & Co., Inc., GLENMARK PHARMACEUTICALS LTD, Amneal Pharmaceuticals LLC, Akums Drugs and Pharmaceuticals Ltd, Astellas Pharma Inc, EVOKE PHARMA, 및 Barhemsys.
주요 개발 사항
 2023년 12월, Akums Drugs and Pharmaceuticals는 인도 CSDCO와 미국 FDA의 승인을 받은 독실아민 + 피리독신 서방정 출시를 발표했습니다. 이 복합제는 임신 중 메스꺼움과 구토 증상 관리에 효과적인 치료법을 제공하는 것을 목표로 합니다.

 2023년 1월, Glenmark Pharmaceuticals Ltd.는 스위스 바이오제약 그룹인 Helsinn과의 독점 라이선스 계약에 따라 화학요법 유발 메스꺼움 및 구토(CINV) 예방을 위한 독특한 정맥 주사 제형인 AKYNZEO I.V.를 인도에 출시했습니다. 포스네투피탄트(235mg)와 팔로노세트론(0.25mg)의 고정 용량 복합제입니다.
 2022년 5월, 타이호 제약(주)은 선택적 NK1 수용체 길항제 항구토제인 아로카리스 정맥주사 235mg(일반명: 포스네투피탄트 염산염)이 국민건강보험(NHI) 급여 대상 약가에 등재되었다고 발표했습니다.

보고서 구매 이유:

• 약물 유형, 적용 분야, 유통 채널 및 지역별 글로벌 항구토제 시장 세분화를 시각화하고 주요 상업적 자산과 기업을 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 모색합니다.

• 모든 세그먼트를 포함한 항구토제 시장의 다양한 데이터가 담긴 엑셀 데이터 시트.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료가 엑셀 파일로 제공됩니다.
글로벌 항구토제 시장 보고서는 약 62개의 표, 57개의 그림, 그리고 182페이지 분량으로 구성될 예정입니다.
2023년 주요 독자층
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
The global antinauseant drugs market reached US$ 2.3 billion in 2023 and is expected to reach US$ 3.7 billion by 2031 growing with a CAGR of 6.2% during the forecast period 2024-2031.
Antinauseants, also known as antiemetics, help prevent or alleviate nausea and vomiting. These two symptoms are prevalent and can be caused by many different conditions, therapies, procedures, and medications. Though vomiting is considered to be a protective reflex of the body to expel toxic substances in the stomach and gut, antiemetic drugs are often necessary to suppress vomiting, especially if there’s severe dehydration.
These drugs are often used to treat conditions such as motion sickness, chemotherapy-induced nausea and vomiting, and postoperative nausea and vomiting. The market is driven by factors such as the rising prevalence of cancer and gastroenteritis and the surge in research and development activities.
Market Dynamics: Drivers
Rising prevalence of cancer and gastroenteritis
The demand for the global antinauseant drugs market is driven by multiple factors. One of the primary factors driving the market is the rising incidence of cancer and the increase in chemotherapy treatments are major drivers of the antinauseant drugs market. Chemotherapy-induced nausea and vomiting (CINV) is a common side effect that requires the use of antiemetic medications to manage.
According to the NIH publication in July 2023, about 70% to 80% of adults with cancer experience chemotherapy‐induced nausea and vomiting (CINV). CINV remains one of the most distressing symptoms associated with cancer therapy and is associated with decreased adherence to chemotherapy.
Similarly, the high prevalence of gastroenteritis globally is also contributing to the demand for antiemetic drugs. Gastroenteritis treatments have witnessed several adverse effects of nausea and vomiting. Antiemetic drugs are useful for controlling such side effects during treatments.
Moreover, key players' awareness programs and drug approvals would propel this market growth in this region. For instance, in October 2023, Astellas Pharma Inc. presented research results at the European Society for Medical Oncology (ESMO) Congress 2023. During this presentation, the company also presented an abstract focusing on the effects of antiemetics on gastric injury and emesis frequency in ferrets.
Also, in April 2022, Evoke Pharma, Inc., was granted new drug product exclusivity by the U.S. Food and Drug Administration (FDA) for Gimoti (metoclopramide) nasal spray. Evoke now has exclusive marketing privileges over three years from the initial date of approval under the Hatch-Waxman Act to protect the product from generic drug competition. Metoclopramide is a dopamine antagonist that is used as a potent antiemetic drug.
Restraints
Factors such as the adverse effects associated with the drugs, lack of awareness among individuals, limited treatment availability, and stringent regulatory requirements, are expected to hamper the market.
For more details on this report - Request for Sample
Segment Analysis
The global antinauseant drugs market is segmented based on drug type, application, distribution channels, and region.
The serotonin-receptor antagonists segment accounted for approximately 45.3% of the global antinauseant drugs market share
The serotonin-receptor antagonists segment is expected to hold the largest market share over the forecast period. 5HT3 antagonists are routinely used as antiemetics postoperatively and during chemotherapy. These include numerous launched products – azasetron, granisetron, indisetron, ondansetron, palonosetron, dolasetron, ramosetron, and tropisetron.
Moreover, key players in the industry drug launches & approvals, and awareness programs would drive this segment growth. For instance, in July 2024, Amneal Pharmaceuticals, Inc. announced the launch of FOCINVEZ, a ready-to-use injectable. Unlike other versions of fosaprepitant, this single-dose vial product is free of Polysorbate 80 does not require reconstitution or dilution, and can be administered directly from the vial using the included vial hanger.
Focinvez and Cinvanti are recommended for use in the treatment of acute and delayed nausea and vomiting, in combination with serotonin (5-HT3) receptor antagonists and a corticosteroid (usually dexamethasone). FOCINVEZ for injection is indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents.
According to the article published by the Canadian Institutes of Health Research in May 2022, Ondansetron, a 5-HT3 antagonist approved in Canada as an antiemetic. This drug is used for nausea and vomiting associated with chemotherapy and post-operation.
Geographical Analysis
North America accounted for approximately 42.2% of the global antinauseant drugs market share.
North America region is expected to hold the largest market share over the forecast period owing to the increasing prevalence of cancer & chemotherapy-induced nausea and vomiting (CINV) and gastroenteritis in the U.S., which would propel this market growth in this region.
According to the American Cancer Society, in December 2023, around 609,820 cancer deaths and 1,958,310 new cancer cases are estimated to occur in the U.S. Thus, the prevalence of such diseases causing vomiting and nausea is anticipated to propel the market growth over the forecast period.
Moreover, key players in the industry strategies such as mergers & acquisitions and drug approvals would propel this market growth in this region. For instance, in January 2022, Cumberland Pharmaceuticals Inc. announced that it had entered into and closed on a definitive agreement to acquire the FDA-approved oncology-supportive care medicine SANCUSO (granisetron transdermal patch), from Kyowa Kirin, Inc. the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. SANCUSO is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment.
Also, in September 2022, Heron Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved APONVIE (aprepitant) injectable emulsion, for intravenous use for the prevention of postoperative nausea and vomiting (PONV) in adults.
Market Segmentation
By Drug Type
• Serotonin-Receptor Antagonists
• Anticholinergics
• Glucocorticoids
• Dopamine Receptor Antagonists
• Neurokinin Receptor Antagonists
• Others
By Application
• Chemotherapy
• Gastroenteritis
• Post-Operative Surgery
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o The rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the antinauseants market include Heron Therapeutics, Inc., TAIHO PHARMACEUTICAL CO., LTD, Pfizer Inc., Merck & Co., Inc., GLENMARK PHARMACEUTICALS LTD, Amneal Pharmaceuticals LLC, Akums Drugs and Pharmaceuticals Ltd, Astellas Pharma Inc, EVOKE PHARMA, and Barhemsys.
Key Developments
 In December 2023, Akums Drugs and Pharmaceuticals announced the launch of Doxylamine + Pyridoxine extended-release tablets, a therapy approved by the CSDCO, India and the USFDA. This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy.
 In January 2023, Glenmark Pharmaceuticals Ltd. launched in India a unique I.V. injection formulation, AKYNZEO I.V., for the prevention of chemotherapy-induced nausea and vomiting (CINV), under an exclusive licensing agreement with Helsinn, a Swiss biopharma group company. AKYNZEO I.V. is a fixed-dose combination of fosnetupitant (235 mg) and palonosetron (0.25 mg).
 In May 2022, Taiho Pharmaceutical Co., Ltd. announced that Arokaris I.V. infusion 235mg (generic name: fosnetupitant chloride hydrochloride), a selective NK1 receptor antagonist antiemetic drug, has been listed on the National Health Insurance (NHI) reimbursement price list.
Why Purchase the Report?
• To visualize the global antinauseant drugs market segmentation based on drug type, application, distribution channels, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the antinauseant drugs market with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.
The global antinauseants drug market report would provide approximately 62 tables, 57 figures, and 182 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

Table of Contents
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Type
3.2. Snippet by Application
3.3. Snippet by Distribution Channels
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Prevalence of Cancer and Gastroenteritis
4.1.1.2. Surge in Research and Development Activities
4.1.2. Restraints
4.1.2.1. Adverse Effects Associated with the Drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Drug Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
6.1.2. Market Attractiveness Index, By Drug Type
6.2. Serotonin-Receptor Antagonists *
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Anticholinergics
6.4. Glucocorticoids
6.5. Dopamine Receptor Antagonists
6.6. Neurokinin Receptor Antagonists
6.7. Others
7. By Application
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application Market Attractiveness Index, By Application
7.2. Chemotherapy *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Gastroenteritis
7.4. Post-Operative Surgery
7.5. Others
8. By Distribution Channels
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
8.1.2. Market Attractiveness Index, By Distribution Channels
8.2. Hospital Pharmacies *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacies
8.4. Online Pharmacies
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Heron Therapeutics, Inc *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. TAIHO PHARMACEUTICAL CO., LTD
11.3. Pfizer Inc
11.4. Merck & Co., Inc
11.5. GLENMARK PHARMACEUTICALS LTD
11.6. Amneal Pharmaceuticals LLC
11.7. Akums Drugs and Pharmaceuticals Ltd
11.8. Astellas Pharma Inc
11.9. EVOKE PHARMA
11.10. Barhemsys
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us

언급된 주요 기업들

Heron Therapeutics, Inc, 4. Key Developments, TAIHO PHARMACEUTICAL CO., LTD, Pfizer Inc, Merck & Co., Inc, GLENMARK PHARMACEUTICALS LTD, Amneal Pharmaceuticals LLC, Akums Drugs and Pharmaceuticals Ltd, Astellas Pharma Inc, EVOKE PHARMA, Barhemsys

표 목록 (Tables)

List of Tables

Table 1 Global Antinauseants Drugs Market Value, By Drug Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Antinauseants Drugs Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Antinauseants Drugs Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Antinauseants Drugs Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Antinauseants Drugs Market Value, By Drug Type, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Antinauseants Drugs Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 7 Global Antinauseants Drugs Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Antinauseants Drugs Market Value, By Application, 2022-2031 (US$ Million)

Table 9 Global Antinauseants Drugs Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Antinauseants Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 11 Global Antinauseants Drugs Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Antinauseants Drugs Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Antinauseants Drugs Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 14 North America Antinauseants Drugs Market Value, By Application, 2022-2031 (US$ Million)

Table 15 North America Antinauseants Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 16 North America Antinauseants Drugs Market Value, By Country, 2022-2031 (US$ Million)

Table 17 Asia-Pacific Antinauseants Drugs Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 18 Asia-Pacific Antinauseants Drugs Market Value, By Application, 2022-2031 (US$ Million)

Table 19 Asia-Pacific Antinauseants Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 20 Asia-Pacific Antinauseants Drugs Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Antinauseants Drugs Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 22 Europe Antinauseants Drugs Market Value, By Application, 2022-2031 (US$ Million)

Table 23 Europe Antinauseants Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 24 Europe Antinauseants Drugs Market Value, By Country, 2022-2031 (US$ Million)

Table 25 South America Antinauseants Drugs Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 26 South America Antinauseants Drugs Market Value, By Application, 2022-2031 (US$ Million)

Table 27 South America Antinauseants Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 28 South America Antinauseants Drugs Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East and Africa Antinauseants Drugs Market Value, By Drug Type, 2022-2031 (US$ Million)

Table 30 Middle East and Africa Antinauseants Drugs Market Value, By Application, 2022-2031 (US$ Million)

Table 31 Middle East and Africa Antinauseants Drugs Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 32 Middle East and Africa Antinauseants Drugs Market Value, By Country, 2022-2031 (US$ Million)

Table 33 Heron Therapeutics, Inc: Overview

Table 34 Heron Therapeutics, Inc: Product Portfolio

Table 35 Heron Therapeutics, Inc: Key Developments

Table 36 TAIHO PHARMACEUTICAL CO., LTD: Overview

Table 37 TAIHO PHARMACEUTICAL CO., LTD: Product Portfolio

Table 38 TAIHO PHARMACEUTICAL CO., LTD: Key Developments

Table 39 Pfizer Inc: Overview

Table 40 Pfizer Inc: Product Portfolio

Table 41 Pfizer Inc: Key Developments

Table 42 Merck & Co., Inc: Overview

Table 43 Merck & Co., Inc: Product Portfolio

Table 44 Merck & Co., Inc: Key Developments

Table 45 GLENMARK PHARMACEUTICALS LTD.: Overview

Table 46 GLENMARK PHARMACEUTICALS LTD.: Product Portfolio

Table 47 GLENMARK PHARMACEUTICALS LTD.: Key Developments

Table 48 Amneal Pharmaceuticals LLC: Overview

Table 49 Amneal Pharmaceuticals LLC: Product Portfolio

Table 50 Amneal Pharmaceuticals LLC: Key Developments

Table 51 Akums Drugs and Pharmaceuticals Ltd: Overview

Table 52 Akums Drugs and Pharmaceuticals Ltd: Product Portfolio

Table 53 Akums Drugs and Pharmaceuticals Ltd: Key Developments

Table 54 Astellas Pharma Inc.: Overview

Table 55 Astellas Pharma Inc.: Product Portfolio

Table 56 Astellas Pharma Inc.: Key Developments

Table 57 EVOKE PHARMA: Overview

Table 58 EVOKE PHARMA: Product Portfolio

Table 59 EVOKE PHARMA: Key Developments

Table 60 Barhemsys: Overview

Table 61 Barhemsys: Product Portfolio

Table 62 Barhemsys: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Antinauseants Drugs Market Value, 2022-2031 (US$ Million)

Figure 2 Global Antinauseants Drugs Market Share, By Drug Type, 2023 & 2031 (%)

Figure 3 Global Antinauseants Drugs Market Share, By Application, 2023 & 2031 (%)

Figure 4 Global Antinauseants Drugs Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 5 Global Antinauseants Drugs Market Share, By Region, 2023 & 2031 (%)

Figure 6 Global Antinauseants Drugs Market Y-o-Y Growth, By Drug Type, 2023-2031 (%)

Figure 7 Serotonin-Receptor Antagonists Antinauseants Drugs Market Value, 2022-2031 (US$ Million)

Figure 8 Anticholinergics Antinauseants Drugs Market Value, 2022-2031 (US$ Million)

Figure 9 Glucocorticoids Antinauseants Drugs Market Value, 2022-2031 (US$ Million)

Figure 10 Dopamine Receptor Antagonists Antinauseants Drugs Market Value, 2022-2031 (US$ Million)

Figure 11 Neurokinin Receptor Antagonists Antinauseants Drugs Market Value, 2022-2031 (US$ Million)

Figure 12 Others Antinauseants Drugs Market Value, 2022-2031 (US$ Million)

Figure 13 Global Antinauseants Drugs Market Y-o-Y Growth, By Application, 2023-2031 (%)

Figure 14 Chemotherapy Application in Global Antinauseants Drugs Market Value, 2022-2031 (US$ Million)

Figure 15 Gastroenteritis Application in Global Antinauseants Drugs Market Value, 2022-2031 (US$ Million)

Figure 16 Post-Operative Surgery Application in Global Antinauseants Drugs Market Value, 2022-2031 (US$ Million)

Figure 17 Others Application in Global Antinauseants Drugs Market Value, 2022-2031 (US$ Million)

Figure 18 Others Application in Global Antinauseants Drugs Market Value, 2022-2031 (US$ Million)

Figure 19 Global Antinauseants Drugs Market Y-o-Y Growth, By Distribution Channel, 2023-2031 (%)

Figure 20 Hospital Pharmacies Distribution Channel in Global Antinauseants Drugs Market Value, 2022-2031 (US$ Million)

Figure 21 Retail Pharmacies Distribution Channel in Global Antinauseants Drugs Market Value, 2022-2031 (US$ Million)

Figure 22 Online Pharmacies Distribution Channel in Global Antinauseants Drugs Market Value, 2022-2031 (US$ Million)

Figure 23 Global Antinauseants Drugs Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 24 North America Antinauseants Drugs Market Value, 2022-2031 (US$ Million)

Figure 25 North America Antinauseants Drugs Market Share, By Drug Type, 2023 & 2031 (%)

Figure 26 North America Antinauseants Drugs Market Share, By Application, 2023 & 2031 (%)

Figure 27 North America Antinauseants Drugs Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 28 North America Antinauseants Drugs Market Share, By Country, 2023 & 2031 (%)

Figure 29 Asia-Pacific Antinauseants Drugs Market Value, 2022-2031 (US$ Million)

Figure 30 Asia-Pacific Antinauseants Drugs Market Share, By Drug Type, 2023 & 2031 (%)

Figure 31 Asia-Pacific Antinauseants Drugs Market Share, By Application, 2023 & 2031 (%)

Figure 32 Asia-Pacific Antinauseants Drugs Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 33 Asia-Pacific Antinauseants Drugs Market Share, By Country, 2023 & 2031 (%)

Figure 34 Europe Antinauseants Drugs Market Value, 2022-2031 (US$ Million)

Figure 35 Europe Antinauseants Drugs Market Share, By Drug Type, 2023 & 2031 (%)

Figure 36 Europe Antinauseants Drugs Market Share, By Application, 2023 & 2031 (%)

Figure 37 Europe Antinauseants Drugs Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 38 Europe Antinauseants Drugs Market Share, By Country, 2023 & 2031 (%)

Figure 39 South America Antinauseants Drugs Market Value, 2022-2031 (US$ Million)

Figure 40 South America Antinauseants Drugs Market Share, By Drug Type, 2023 & 2031 (%)

Figure 41 South America Antinauseants Drugs Market Share, By Application, 2023 & 2031 (%)

Figure 42 South America Antinauseants Drugs Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 43 South America Antinauseants Drugs Market Share, By Country, 2023 & 2031 (%)

Figure 44 Middle East and Africa Antinauseants Drugs Market Value, 2022-2031 (US$ Million)

Figure 45 Middle East and Africa Antinauseants Drugs Market Share, By Drug Type, 2023 & 2031 (%)

Figure 46 Middle East and Africa Antinauseants Drugs Market Share, By Application, 2023 & 2031 (%)

Figure 47 Middle East and Africa Antinauseants Drugs Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 48 Heron Therapeutics, Inc: Financials

Figure 49 TAIHO PHARMACEUTICAL CO., LTD: Financials

Figure 50 Pfizer Inc: Financials

Figure 51 Merck & Co., Inc: Financials

Figure 52 GLENMARK PHARMACEUTICALS LTD.: Financials

Figure 53 Amneal Pharmaceuticals LLC: Financials

Figure 54 Akums Drugs and Pharmaceuticals Ltd: Financials

Figure 55 Astellas Pharma Inc.: Financials

Figure 56 EVOKE PHARMA: Financials

Figure 57 Barhemsys: Financials